Effectiveness and cost-effectiveness of RSV infant and maternal immunization programs: A case study of Nunavik, Canada

Effectiveness and cost-effectiveness of RSV infant and maternal immunization programs: A case study of Nunavik, Canada

Background: Despite passive immunization with palivizumab to select high-risk children under two years of age, the health and economic burden of respiratory syncytial virus (RSV) remains substantial. We evaluated the effectiveness and cost-effectiveness of immunization programs with new generations...

Full description

Bibliographic Details
Main Authors: Shokoofeh Nourbakhsh, Affan Shoukat, Kevin Zhang, Guillaume Poliquin, Donna Halperin, Holden Sheffield, Scott A. Halperin, Joanne M. Langley, Seyed M. Moghadas
Format: Article
Language:English
Published: Elsevier 2021-11-01
Series:EClinicalMedicine
Subjects:
Respiratory syncytial virus
Vaccines
Long-acting monoclonal antibody
Maternal vaccine
Palivizumab
Immunization programs
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537021004211

Internet

http://www.sciencedirect.com/science/article/pii/S2589537021004211

Similar Items